Aclaris Therapeutics, Inc.

NasdaqGS:ACRS Lagerbericht

Marktkapitalisierung: US$327.9m

Aclaris Therapeutics Management

Management Kriterienprüfungen 4/4

Aclaris Therapeutics CEO ist Neal Walker , ernannt in Jul 2012, hat eine Amtszeit von 12.33 Jahren. besitzt direkt 1.93% der Aktien des Unternehmens, im Wert von $6.32M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.4 Jahre bzw. 10.5 Jahre.

Wichtige Informationen

Neal Walker

Geschäftsführender

US$73.5k

Gesamtvergütung

Prozentsatz des Geschäftsführergehaltsn/a
Amtszeit als Geschäftsführer12.3yrs
Eigentum des Geschäftsführers1.9%
Durchschnittliche Amtszeit des Managements2.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder10.5yrs

Jüngste Management Updates

Recent updates

Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Nov 12
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?

Aug 08
Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth?

We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

May 03
We're Keeping An Eye On Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up

Mar 07
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up

Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Mar 01
Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Jan 19
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Nov 11
Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Nov 03
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results

Aug 10
Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results

What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today

Aug 08
What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today

Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Jun 06
Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely

Apr 07
We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Dec 21
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aclaris initiated as a buy at BTIG on potential of zunsemetinib for autoimmune conditions

Oct 06

Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aug 26
Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation

Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata

Aug 25

Aclaris Therapeutics gets a new COO

Aug 01

Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth

May 28
Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth

We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Dec 14
We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Neal Walker im Vergleich zu den Einnahmen von Aclaris Therapeutics verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

-US$37m

Jun 30 2024n/an/a

-US$59m

Mar 31 2024n/an/a

-US$77m

Dec 31 2023US$74kn/a

-US$88m

Sep 30 2023n/an/a

-US$115m

Jun 30 2023n/an/a

-US$105m

Mar 31 2023n/an/a

-US$96m

Dec 31 2022US$6mUS$590k

-US$87m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$83m

Mar 31 2022n/an/a

-US$81m

Dec 31 2021US$7mUS$567k

-US$91m

Sep 30 2021n/an/a

-US$82m

Jun 30 2021n/an/a

-US$71m

Mar 31 2021n/an/a

-US$65m

Dec 31 2020US$2mUS$424k

-US$51m

Sep 30 2020n/an/a

-US$57m

Jun 30 2020n/an/a

-US$69m

Mar 31 2020n/an/a

-US$102m

Dec 31 2019US$3mUS$500k

-US$114m

Sep 30 2019n/an/a

-US$118m

Jun 30 2019n/an/a

-US$115m

Mar 31 2019n/an/a

-US$79m

Dec 31 2018US$4mUS$550k

-US$82m

Sep 30 2018n/an/a

-US$81m

Jun 30 2018n/an/a

-US$79m

Mar 31 2018n/an/a

-US$86m

Dec 31 2017US$810kUS$510k

-US$50m

Vergütung im Vergleich zum Markt: NealDie Gesamtvergütung ($USD73.50K) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD2.16M).

Entschädigung vs. Einkommen: NealDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Neal Walker (54 yo)

12.3yrs

Amtszeit

US$73,500

Vergütung

Dr. Neal S. Walker, D.O. & M.D., is Venture Partner of Forge Life Science Partners. He Co-founded Aclaris Therapeutics, Inc. in 2012 and has been its Director since July 2012 and serves as its Chairman sin...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Neal Walker
Co-Founder12.3yrsUS$73.50k1.93%
$ 6.3m
Kevin Balthaser
Chief Financial Officer1.8yrsUS$2.34m0.035%
$ 113.3k
Joseph Monahan
Chief Scientific Officer3.8yrsUS$2.26m0.26%
$ 858.2k
James Loerop
Chief Business Officer2.8yrsUS$2.33m0.048%
$ 156.1k
Matthew Rothman
General Counsel & Corporate Secretary2.4yrskeine Datenkeine Daten
Jon Jacobsen
Senior Vice President of Chemistryno datakeine Datenkeine Daten
Steve Tucker
Senior Vice President of Project Leadershipless than a yearkeine Datenkeine Daten
Ajay Aggarwal
Senior Vice President of Clinical Developmentless than a yearkeine Datenkeine Daten

2.4yrs

Durchschnittliche Betriebszugehörigkeit

56.5yo

Durchschnittliches Alter

Erfahrenes Management: ACRSDas Führungsteam des Unternehmens gilt als erfahren (2.4 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Neal Walker
Co-Founder12.3yrsUS$73.50k1.93%
$ 6.3m
Vincent Milano
Independent Director4.8yrsUS$180.38k0.018%
$ 57.5k
Mark Bradshaw
Member of Advisory Boardno datakeine Datenkeine Daten
James Leyden
Member of Advisory Boardno datakeine Datenkeine Daten
Klaus Theobald
Member of Advisory Boardno datakeine Datenkeine Daten
Anand Mehra
Independent Director10.2yrsUS$194.38k0.061%
$ 199.0k
Pearl Grimes
Member of Advisory Boardno datakeine Datenkeine Daten
Guy Webster
Member of Advisory Boardno datakeine Datenkeine Daten
Christopher Molineaux
Lead Independent Director10.8yrsUS$206.88k0.074%
$ 244.0k
Kenneth Beer
Member of Advisory Boardno datakeine Datenkeine Daten
Leslie Baumann
Member of Advisory Boardno datakeine Datenkeine Daten
Andrew Ondo
Member of Advisory Boardno datakeine Datenkeine Daten

10.5yrs

Durchschnittliche Betriebszugehörigkeit

60yo

Durchschnittliches Alter

Erfahrener Vorstand: ACRSDie Vorstandsmitglieder sind sehr erfahren ( 10.5 ).